The K1 protein of Kaposi's sarcoma-associated herpesvirus activates the Akt signaling pathway.

in Journal of virology by Christine C Tomlinson, Blossom Damania

TLDR

  • KSHV is a virus that causes Kaposi's sarcoma and other diseases. The K1 protein of KSHV is responsible for these diseases by promoting cell survival and preventing virally infected cells from undergoing apoptosis. The study found that K1 targets the PI3K pathway, leading to Akt activation and FKHR inhibition, which promotes cell survival and contributes to KSHV pathogenesis. The study also identified small molecule inhibitors of the PI3K pathway or the FKHR transcription factor family as potential therapeutic agents for KSHV-associated diseases.

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV) has been implicated in Kaposi's sarcoma, as well as in primary effusion lymphoma and multicentric Castleman's disease. The K1 protein of KSHV has been shown to induce cellular transformation and focus formation and to deregulate B-lymphocyte signaling pathways by functionally mimicking the activated B-cell receptor complex. Here we show that expression of K1 in B lymphocytes targets the phosphatidylinositol-3 kinase pathway, leading to the activation of the Akt kinase and the inhibition of the phosphatase PTEN. We also demonstrate that activation of Akt by the K1 protein leads to the phosphorylation and inhibition of members of the forkhead (FKHR) transcription factor family, which are key regulators of cell cycle progression and apoptosis. We demonstrate that K1 can inhibit apoptosis induced by the FKHR proteins and by stimulation of the Fas receptor. Our observations suggest that the K1 viral protein promotes cell survival pathways and may contribute to KSHV pathogenesis by preventing virally infected cells from undergoing apoptosis prematurely.

Overview

  • The study investigates the role of Kaposi's sarcoma-associated herpesvirus (KSHV) in Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. The study focuses on the K1 protein of KSHV and its ability to induce cellular transformation and deregulate B-lymphocyte signaling pathways. The primary objective of the study is to understand the mechanisms by which K1 promotes cell survival pathways and contributes to KSHV pathogenesis. The study uses B lymphocytes as a model system to investigate the effects of K1 on cellular signaling pathways and apoptosis.

Comparative Analysis & Findings

  • The study compares the effects of K1 on B lymphocytes with and without the activation of the phosphatidylinositol-3 kinase (PI3K) pathway. The results show that K1 targets the PI3K pathway, leading to the activation of the Akt kinase and the inhibition of the phosphatase PTEN. The study also demonstrates that activation of Akt by K1 leads to the phosphorylation and inhibition of members of the forkhead (FKHR) transcription factor family, which are key regulators of cell cycle progression and apoptosis. The study finds that K1 can inhibit apoptosis induced by the FKHR proteins and by stimulation of the Fas receptor. These findings suggest that K1 promotes cell survival pathways and may contribute to KSHV pathogenesis by preventing virally infected cells from undergoing apoptosis prematurely.

Implications and Future Directions

  • The study's findings have significant implications for the understanding of KSHV pathogenesis and the development of new therapeutic strategies for Kaposi's sarcoma and other KSHV-associated diseases. The study identifies the PI3K pathway as a key target for K1-mediated cellular transformation and apoptosis inhibition. The study also highlights the importance of the FKHR transcription factor family in regulating cell cycle progression and apoptosis. Future research could focus on the development of small molecule inhibitors of the PI3K pathway or the FKHR transcription factor family as potential therapeutic agents for KSHV-associated diseases. Additionally, future research could investigate the role of K1 in other viral infections and cancer progression.